Company Overview

Cellectis S.A. is a French biotechnology company focused on developing gene-edited cell and gene therapies, primarily for oncology applications. The company operates in the biotechnology and life sciences industries and specializes in genome engineering using proprietary gene-editing technologies. Cellectis is best known for its work in allogeneic CAR-T cell therapies, which are designed as “off-the-shelf” treatments derived from healthy donors rather than a patient’s own cells. Its core technology platform is based on TALEN (Transcription Activator-Like Effector Nucleases) gene-editing technology, which the company uses to engineer immune cells for therapeutic applications.

The company’s primary revenue sources have included collaboration agreements, licensing arrangements, research partnerships, and milestone payments tied to development programs. Cellectis has historically partnered with major pharmaceutical and biotechnology firms to advance its pipeline and platform technologies. Founded in 1999 in France, the company evolved from an early-stage genome engineering research enterprise into a clinical-stage biotechnology company with operations spanning Europe and North America. Over time, it expanded its focus from broad gene-editing applications toward immuno-oncology and allogeneic cell therapy development.

Business Operations

Cellectis conducts operations through multiple business activities centered on gene editing and cell therapy development. Its principal operations include the development of allogeneic CAR-T therapies under its therapeutic programs and the licensing of its gene-editing technologies. The company has historically reported activities associated with therapeutic product development and platform technology collaborations. Its therapeutic pipeline has included candidates targeting hematologic malignancies, including acute lymphoblastic leukemia and non-Hodgkin lymphoma. Manufacturing and process development capabilities support the production of engineered cell therapies for clinical use.

The company operates internationally, with significant activities in France and the United States. Cellectis maintains research and manufacturing capabilities through subsidiaries including Cellectis, Inc. and has operated manufacturing infrastructure in the U.S. to support clinical and commercial scalability. The company has entered partnerships with organizations such as Servier and previously with Pfizer related to immuno-oncology development programs. Its technology assets include proprietary TALEN gene-editing systems and electroporation technologies used to modify immune cells for therapeutic applications.

Strategic Position & Investments

Cellectis has positioned itself as a developer of allogeneic cell therapies designed to reduce manufacturing complexity and improve treatment accessibility compared with autologous CAR-T therapies. Its strategic direction has emphasized advancing wholly owned clinical programs while monetizing and expanding its gene-editing platform through collaborations and licensing agreements. The company has invested in manufacturing capabilities and process optimization intended to support scalable production of engineered cell therapies.

The company has also pursued strategic partnerships to offset development costs and accelerate commercialization opportunities. Notable transactions have included collaboration agreements involving oncology-focused cell therapies and gene-editing applications. Cellectis has maintained investments in research related to next-generation gene-editing approaches and immune-cell engineering technologies. Public filings and company disclosures indicate continued focus on expanding clinical-stage assets and improving the safety and persistence characteristics of allogeneic CAR-T candidates. Some pipeline prioritization decisions and program restructuring activities have occurred over time as the company adjusted resource allocation and development strategy.

Geographic Footprint

Cellectis is headquartered in Paris, France, and maintains operational and research activities in both Europe and North America. Its U.S. presence has included operations in New York and manufacturing activities supporting clinical development. The company’s international footprint reflects its strategy of accessing major biotechnology ecosystems, regulatory markets, and clinical research infrastructure.

The company’s collaborations and clinical activities have extended across multiple regions, including the United States and parts of Europe. Cellectis has participated in international clinical trials and strategic partnerships with global pharmaceutical companies. Its operational structure supports cross-border research, manufacturing, and commercialization initiatives within the biotechnology and immunotherapy sectors.

Leadership & Governance

Cellectis was founded by French scientist André Choulika, who has played a central role in shaping the company’s scientific and strategic direction. Leadership has consistently emphasized innovation in genome engineering, development of scalable allogeneic therapies, and advancement of proprietary gene-editing technologies. The company operates under a governance structure typical of publicly traded biotechnology companies, with oversight from executive leadership and a board of directors.

Key executives have included:

• André Choulika – Chief Executive Officer and Chairman
• Blagica Bottigliero – Senior executive leadership roles in corporate and business operations
• Mark Frattini – Chief Financial Officer
• Philippe Duchateau – Scientific leadership roles related to genome engineering and innovation
• Mathieu Simon – Chief Operating Officer

Executive roles and organizational structures have evolved over time based on operational needs and strategic priorities. Certain leadership appointments or role changes may vary across reporting periods based on the company’s most recent public disclosures.